Početna › Wilmsov tumor
Kliničke studije za Wilmsov tumor koje traže sudionike u SAD-u
17 studija za Wilmsov tumor traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Washington, DC7 studija
- Memphis, TN6 studija
- Atlanta, GA5 studija
- Boston, MA4 studija
- Chicago, IL4 studija
- St. Louis, MO4 studija
- Greenburgh, NY4 studija
- Cincinnati, OH4 studija
- Mountain View, CA4 studija
- New York City, NY4 studija
- Los Angeles, CA4 studija
- Houston, TX4 studija
- Philadelphia, PA4 studija
- Minneapolis, MN4 studija
- Aurora, CO4 studija
- Ann Arbor, MI3 studija
- Birmingham, AL3 studija
Po državama
- Alabama3 studija
- Colorado4 studija
- Distrikt Columbia7 studija
- Florida3 studija
- Georgia5 studija
- Illinois4 studija
- Kalifornija5 studija
- Massachusetts4 studija
- Michigan3 studija
- Minnesota5 studija
- Missouri4 studija
- New York6 studija
- Ohio5 studija
- Pennsylvania4 studija
- Tennessee6 studija
- Texas6 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
U tijeku regrutacijaFaza 2
Od 12 do 39 godina · Oba spola · Ažurirano 29. ruj 2026. · NCT04616560Biomarkers of Resiliency In Childhood Cancer Surgery
U tijeku regrutacijaOpažajna studija
Od 3 do 25 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06674811A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
U tijeku regrutacijaFaza 2
Do 30 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT04851119Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
U tijeku regrutacijaFaza 1
Od 1 do 23 godina · Oba spola · Ažurirano 13. kol 2026. · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. kol 2026. · NCT04715191Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 30. lip 2026. · NCT06625190B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
U tijeku regrutacijaFaza 1
Do 21 godina · Oba spola · Ažurirano 19. svi 2026. · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 19. svi 2026. · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
U tijeku regrutacijaFaza 2
12 Months · Oba spola · Ažurirano 6. svi 2026. · NCT05985161Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
U tijeku regrutacijaFaza 2
Sve dobne skupine · Oba spola · Ažurirano 23. tra 2026. · NCT04968990Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04308330Pencil Beam Scanning in Patients With Renal Tumors
U tijeku regrutacijaRana faza 1
Od 0 do 30 godina · Oba spola · Ažurirano 15. tra 2026. · NCT03810651Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
U tijeku regrutacijaFaza 1
Od 1 do 26 godina · Oba spola · Ažurirano 17. velj 2026. · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
U tijeku regrutacijaFaza 1
Do 21 godina · Oba spola · Ažurirano 3. stu 2025. · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
U tijeku regrutacijaFaza 2
18 Months – 40 Years · Oba spola · Ažurirano 12. kol 2025. · NCT05135975International PPB/DICER1 Registry
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
0 Minutes – 100 Years · Oba spola · Ažurirano 30. sij 2025. · NCT03382158Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.